Immunotherapy of hepatocellular carcinoma

被引：69

作者：

Greten, Tim F. ^{[1
]}

Manns, Michael P. ^{[1
]}

Korangy, Firouzeh ^{[1
]}

机构：

[1] Hannover Med Sch, Dept Gastroenterol Hepatol & Endocrinol, Hannover, Germany

来源：

JOURNAL OF HEPATOLOGY | 2006年 / 45卷 / 06期

关键词：

D O I：

10.1016/j.jhep.2006.09.004

中图分类号：

R57 [消化系及腹部疾病];

学科分类号：

摘要：

[No abstract available]

引用

页码：868 / 878

页数：11

共 158 条

[1] LOW-DOSE INTERLEUKIN-2 SUBCUTANEOUS IMMUNOTHERAPY IN ASSOCIATION WITH THE PINEAL HORMONE MELATONIN AS A FIRST-LINE THERAPY IN LOCALLY ADVANCED OR METASTATIC HEPATOCELLULAR-CARCINOMA [J].

ALDEGHI, R ;

LISSONI, P ;

BARNI, S ;

ARDIZZOIA, A ;

TANCINI, G ;

PIPERNO, A ;

POZZI, M ;

RICCI, G ;

CONTI, A ;

MAESTRONI, GJM .

EUROPEAN JOURNAL OF CANCER, 1994, 30A (02) :167-170

[2] Activation of dendritic cells by local ablation of hepatocellular carcinoma [J].

Ali, MY ;

Grimm, CF ;

Ritter, M ;

Mohr, L ;

Allgaier, HP ;

Weth, R ;

Bocher, WO ;

Endrulat, K ;

Blum, HE ;

Geissler, M .

JOURNAL OF HEPATOLOGY, 2005, 43 (05) :817-822

[3] Analysis of CD4+ T-cell responses to a novel α-fetoprotein-derived epitope in hepatocellular carcinoma patients [J].

Alisa, A ;

Ives, A ;

Pathan, AA ;

Navarrete, CV ;

Williams, R ;

Bertoletti, A ;

Behboudi, S .

CLINICAL CANCER RESEARCH, 2005, 11 (18) :6686-6694

[4] Ex vivo detectable human CD8 T-cell responses to cancer-testis antigens [J].

Baumgaertner, P ;

Rufer, N ;

Devevre, E ;

Derre, L ;

Rimoldi, D ;

Geldhof, C ;

Voelter, V ;

Liénard, D ;

Romero, P ;

Speiser, DE .

CANCER RESEARCH, 2006, 66 (04) :1912-1916

[5] Local/regional and systemic treatments of hepatocellular carcinoma [J].

Beaugrand, M ;

N'kontchou, G ;

Seror, O ;

Ganne, N ;

Trinchet, JC .

SEMINARS IN LIVER DISEASE, 2005, 25 (02) :201-211

[6] Increased levels of interleukin-10 in serum from patients with hepatocellular carcinoma correlate with profound numerical deficiencies and immature phenotype of circulating dendritic cell subsets [J].

Beckebaum, S ;

Zhang, X ;

Chen, X ;

Yu, ZY ;

Frilling, A ;

Dworacki, G ;

Grosse-Wilde, H ;

Broelsch, CE ;

Gerken, G ;

Cicinnati, VR .

CLINICAL CANCER RESEARCH, 2004, 10 (21) :7260-7269

[7]

BEISSERT S, 1995, J IMMUNOL, V154, P1280

[8] NO SYNERGISTIC ACTIVITY OF EPIRUBICIN AND INTERFERON-ALPHA-2B IN THE TREATMENT OF HEPATOCELLULAR-CARCINOMA [J].

BOKEMEYER, C ;

KYNAST, B ;

HARSTRICK, A ;

LAAGE, E ;

SCHMOLL, E ;

VONWUSSOW, P ;

SCHMOLL, HJ .

CANCER CHEMOTHERAPY AND PHARMACOLOGY, 1995, 35 (04) :334-338

[9] Naturally acquired MAGE-A10- and SSX-2-specific CD8+ T cell responses in patients with hepatocellular carcinoma [J].

Bricard, G ;

Bouzourene, H ;

Martinet, O ;

Rimoldi, D ;

Halkic, N ;

Gillet, M ;

Chaubert, P ;

MacDonald, HR ;

Romero, P ;

Cerottini, JC ;

Speiser, DE .

JOURNAL OF IMMUNOLOGY, 2005, 174 (03) :1709-1716

[10] Focus on hepatocellular carcinoma [J].

Bruix, J ;

Boix, L ;

Sala, M ;

Llovet, JM .

CANCER CELL, 2004, 5 (03) :215-219

← 1 2 3 4 5 6 7 8 9 10 →